2021-12-20T14:53:32-06:00 2020-12-31 911194016 CLARK NUBER PS 10900 NE 4TH STREET SUITE 1400 BELLEVUE WA 98004 990 2020-01-01 911608978 INFECTIOUS DISEASE RESEARCH INSTITUTE INFE 2063810883 1616 EASTLAKE AVE E NO 400 SEATTLE WA 98102 NEIL O'CONNOR PRESIDENT & COO 2063810883 2021-12-14 1 NEIL OCONNOR 999009999 SARA ELIZABETH JONES HYRE P00235495 4254544919 2021-12-14 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z COREY CASPER 1616 EASTLAKE AVE E NO 400 SEATTLE WA 98102 15591788 0 X WWW.IDRI.ORG X 1993 WA DEVELOP VACCINES, ADJUVANTS, DIAGNOSTICS & DRUGS TO PREVENT, DETECT & TREAT INFECTIOUS DISEASES OF GLOBAL IMPORTANCE. X 1 0 69 0 0 0 11251999 3584439 11179733 10969518 -465831 -1719650 10115 508253 21976016 13342560 1739026 0 0 0 12177738 6532666 0 0 0 15130135 13282085 29046899 19814751 -7070883 -6472191 16784379 13563097 20143498 19973185 -3359119 -6410088 X AS A "NONPROFIT BIOTECH," IDRI COMBINES THE HIGH-QUALITY SCIENCE OF A RESEARCH ORGANIZATION WITH THE PRODUCT DEVELOPMENT CAPABILITIES OF A BIOTECH COMPANY TO CREATE NEW DIAGNOSTICS, DRUGS AND VACCINES FOR INFECTIOUS DISEASES AND IMPROVE THE HEALTH OF THE WORLD. 0 1 5191788 3679456 VACCINE RESEARCH - IDRI SCIENTISTS ARE DEVELOPING INNOVATIVE TECHNOLOGIES THAT ENABLE VACCINES WHICH ARE HIGHLY EFFECTIVE, DURABLE, AND ACCESSIBLE TO PEOPLE ACROSS THE GLOBE. THESE VACCINES HAVE FEATURES THAT MAKE THEM UNIQUELY SUITED FOR THE PREVENTION OF INFECTIOUS DISEASE (INCLUDING PANDEMICS), CANCER AND ALLERGIC DISEASES, AND CAN ALSO BE USED AS THERAPEUTIC AGENTS. CURRENT TARGETS INCLUDE COVID-19, INFLUENZA, TUBERCULOSIS, HIV, ZIKA, YELLOW FEVER, LEPROSY, LEISHMANIASIS, AND CHIKUNGUNYA. IDRI SCIENTISTS ARE DEVELOPING AND MANUFACTURING NEXT GENERATION VACCINES INCLUDING THOSE BASED ON RNA AND ADJUVANT PROTEIN PLATFORMS TO RESPOND QUICKLY WHEN DISEASE OUTBREAKS OCCUR. IDRI HAS A ROBUST PIPELINE OF NEW VACCINE CANDIDATES WHICH ARE MOVING SUCCESSFULLY THROUGH EARLY CLINICAL TRIALS. 4460727 4069409 IDRI'S CLINICAL GROUP DESIGNS AND CONDUCTS EARLY-STAGE CLINICAL TRIALS TO TEST THE VACCINE CANDIDATES IDENTIFIED BY IDRI SCIENTISTS OR COLLABORATORS. THROUGH OUR NETWORK OF GLOBAL COLLABORATIONS AND WITH DEEP KNOWLEDGE OF REGULATORY PROCESSES AND PROCEDURES IN THE US AND FOREIGN COUNTRIES, THE CLINICAL TEAM IS ABLE TO LAUNCH CLINICAL TRIALS ALMOST ANYWHERE IN THE WORLD. 2504990 2021609 MANUFACTURING - IDRI HAS CREATED MANUFACTURING CAPABILITIES THAT ALLOW RAPID SCALE-UP AND PRODUCTION OF VACCINES FOR USE IN PHASE 1 AND PHASE 2 CLINICAL TRIALS AND COMPLETES IDRI'S UNIQUE VACCINE DISCOVERY-DEVELOPMENT PROCESS. WHEN IDRI SCIENTISTS IDENTIFY A VACCINE CANDIDATE IN THE LABORATORY, THIS MANUFACTURING CAPABILITY ENABLES THEM TO APPLY THAT DISCOVERY BY PRODUCING VACCINES UNDER CONTROLLED CONDITIONS SO THAT THEY ARE SUITABLE FOR USE IN HUMAN STUDIES. THIS ENABLES IDRI TO MOVE A VACCINE FROM LATE-STAGE RESEARCH TO EARLY CLINICAL STUDIES. IDRI'S MANUFACTURING SUITE IS "GOOD MANUFACTURING PRACTICE" (GMP)-CERTIFIED AND IS AN INVALUABLE RESOURCE TO IDRI SCIENTISTS AND BIOTECHNOLOGY DEVELOPERS IN THE NON-PROFIT, ACADEMIC, AND FOR-PROFIT SECTORS. 527271 770361 ADJUVANT RESEARCH - ADJUVANTS ARE POWERFUL SYNTHETIC SUBSTANCES WHICH CAN BE ADDED TO VACCINES TO ENHANCE THE QUANTITY, QUALITY, DIVERSITY, AND DURATION OF THE BODY'S IMMUNE RESPONSE. IDRI SCIENTISTS ARE PIONEERS IN OPTIMIZING ADJUVANT AND VACCINE FORMULATIONS AND IDRI POSSESS THE WORLD'S LEADING PORTFOLIO OF ADJUVANT FORMULATIONS. IDRI SCIENTISTS HAVE DEVELOPED MOLECULES THAT STIMULATE AN EARLY WARNING IN THE BODY'S IMMUNE SYSTEM CAUSING A POWERFUL, BROAD IMMUNE RESPONSE TO DEFINED ANTIGENS. THEY ARE FOCUSING ON HOW THAT STIMULATION TRANSLATES INTO BROAD PROTECTIION AGAINST VARIOUS PATHOGENS AND HELPS REDUCE THE REQUIRED VACCINE DOSE AND NUMBER OF SHOTS A PATIENT MAY NEED. IDRI'S DEEP EXPERIENCE IN ADJUVANT DEVELOPMENT PROVIDES A UNIQUE DEPTH OF KNOWLEDGE OF REGULATORY REQUIREMENTS OF BOTH US AND FOREIGN REGULATORY AGENCIES. 160587 428683 PROCESS AND PRODUCT DEVELOPMENT - MODERN VACCINES ARE INCREASINGLY COMPLEX, AND THEIR DESIGN NEEDS TO BE TAILORED TO SUIT A SPECIFIC SET OF TARGET PRODUCT PROFILES. FOR EXAMPLE, VACCINES FOR GLOBAL HEALTH APPLICATIONS IN RESOURCE-LIMITED SETTINGS OFTEN NEED TO BE STABLE AT ROOM TEMPERATURES, AND VACCINES DIRECTED AT RESPIRATORY PATHOGENS OR DESIGNED FOR USE IN POPULATIONS WITH VACCINE HESITANCY MAY BEST BE DELIVERED INTRA-NASALLY. IDRI SCIENTISTS ARE WORLD-EXPERTS AT DEVELOPING PROCESSES FOR VACCINE MANUFACTURE OR ADVANCING NOVEL PRODUCTS THAT MEET THE NEEDS OF VACCINE DEVELOPERS BOTH WITHIN IDRI AND EXTERNALLY AMONG THE DOZENS OF ACADEMIC, NON-PROFIT, AND COMMERCIAL PARTNERS. 687858 1199044 12845363 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 1 23 0 69 1 0 0 0 0 0 0 0 0 0 0 0 0 X 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 0 X NEIL O'CONNOR 2063810883 1616 EASTLAKE AVE E SUITE 400 SEATTLE WA 98102 COREY CASPER CEO 40.00 X 397292 0 16073 ANNA MARIE BECKMANN EVP, PRODUCT DEVELOPMENT 40.00 X 207514 0 26192 CHRISTOPHER FOX VP, FORMULATIONS 40.00 X 171814 0 28190 LINDA HAWKINS DIR. QUALITY ASSURANCE & COMPLIANCE 40.00 X 160321 0 24254 NEIL O'CONNOR PRESIDENT & COO 32.00 X 162179 0 21130 ROBRICK SMITH DIRECTOR, INFORMATION TECHNOLOGY 40.00 X 156276 0 25928 CYNTHIA SHUMATE GENERAL COUNSEL & SEC. THRU 07/20 40.00 X 157812 0 14877 ERIK LAURSEN DIR. GMP OPERATIONS 32.00 X 131527 0 15617 DARREN KLEMKOW DIRECTOR, FACILITIES & PROCUREMENT 40.00 X 115589 0 24918 JEFFREY GUDERIAN DIRECTOR, LABORATORY MANAGEMENT 40.00 X 111372 0 16402 WINSTON WICOMB DIRECTOR, VIVARIUM THRU 05/20 40.00 X 117795 0 4635 SHELLY CROCKER RECEIVER 40.00 X 0 0 0 1889491 0 218216 16 0 1 0 FHI CLINICAL INC 359 BLACKWELL ST STE 200 DURHAM NC 27701 CLINICAL SERVICES 2654731 SHELLY CROCKER LLC 4616 25TH AVENUE NE 401 SEATTLE WA 98105 RECEIVERSHIP 517900 CAIRNCROSS & HEMPELMANN 524 SECOND AVENUE STE 500 SEATTLE WA 98104 LEGAL 379579 UNIVERSITY OF VIRGINIA PO BOX 400195 CHARLOTTESVILLE VA 22904 CLINICAL SERVICES 332899 NOW CFO 5251 S GREEN STREET MURRAY UT 84123 ACCOUNTING CONSULTING 272875 8 3304857 279582 3584439 SERVICES AND CONTRACTS 541700 8958713 8958713 LICENSING 541700 2010805 2010805 10969518 532 532 529046 2249228 -1720182 -1720182 -1720182 LICENSING WRITE-OFF 900099 314372 314372 PATENT FEES REIMB. 900099 121334 121334 REFUNDS 900099 57623 57623 14924 14924 508253 13342560 10969518 0 -1211397 1397163 433710 963453 4084274 2974135 1110139 140247 95475 44772 493608 396188 97420 417374 263116 154258 932550 932550 1135470 1135470 455503 455503 697002 466509 230493 940 650 290 80830 21753 59077 253641 21634 232007 249342 249342 2335342 1681446 653896 2290 1115 1175 4855 544 4311 112535 112535 1933352 1664515 268837 139380 139380 SUBCONTRACTS 3429582 3429582 LAB SUPPLIES 1141884 1138310 3574 REPAIRS & MAINTENANCE 255519 255519 BUSINESS TAXES 104115 104115 17953 1162 16791 19814751 12845363 6969388 0 560115 675602 883783 1587211 1797762 0 1072560 3268294 777142 391189 165515 154808 19447311 12063922 11418648 7383389 108854 102604 16784379 13563097 2457537 3996647 3562652 5341627 1524610 919046 0 1927711 12598699 7788154 20143498 19973185 X -5345681 -7294061 1986562 883973 -3359119 -6410088 16784379 13563097 X -6472191 3421222 X X 0 0 1 0 X 10055782 11656120 14143765 11251999 3584439 50692105 10055782 11656120 14143765 11251999 3584439 50692105 2821490 47870615 1003630 941071 45438 13436 532 2004107 8216 70307 -536 -13 508253 586227 53282439 56391145 0.89840 0.83860 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - 2017 AMOUNT: $ 70,307. 2020 AMOUNT: $ 5,857. REIMBURSEMENTS - 2016 AMOUNT: $ 413. 2020 AMOUNT: $ 121,334. STORAGE - 2016 AMOUNT: $ 7,803. CURRENCY EXCHANGE - 2018 AMOUNT: $ -536. 2019 AMOUNT: $ -13. REFUNDS - 2020 AMOUNT: $ 66,690. LICENSING WRITE-OFF - 2020 AMOUNT: $ 314,372. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 11377971 5884227 5493744 8069340 6179695 1889645 7383389 DEFERRED RENT 7788154 7788154 EAST ASIA AND THE PACIFIC 0 0 LEGAL N/A 47000 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 LEGAL N/A 31000 NORTH AMERICA 0 0 LEGAL, SOFTWARE N/A 8000 SOUTH AMERICA 0 0 LEGAL N/A 6000 SOUTH ASIA 0 0 LEGAL N/A 6000 RUSSIA AND NEIGHBORING STATES 0 0 LEGAL N/A 5000 MIDDLE EAST AND NORTH AFRICA 0 0 LEGAL N/A 3000 SUB-SAHARAN AFRICA 0 0 LEGAL N/A 1000 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICE SUBCONTRACT 73629 0 0 0 0 0 0 107000 73629 180629 1 0 0 0 0 0 PART I, LINE 3: THE EXPENDITURES REPORTED ON SCHEDULE F, PART I, LINE 3 ARE ON ACCRUAL BASIS OF ACCOUNTING. PART III ACCOUNTING METHOD: SCHEDULE F, PART IV, LINE 1: FORM 926 IS NOT REQUIRED TO BE FILED BECAUSE THE TRANSFER TO A FOREIGN CORPORATION DOES NOT MEET THE REPORTING REQUIREMENTS IN THE IRC SEC. 6038(A)(1)(A). X 0 0 0 0 0 0 0 0 0 COREY CASPER CEO 397292 0 0 0 0 0 11400 0 4673 0 413365 0 0 0 ANNA MARIE BECKMANN EVP, PRODUCT DEVELOPMENT 207514 0 0 0 0 0 8301 0 17891 0 233706 0 0 0 CHRISTOPHER FOX VP, FORMULATIONS 171814 0 0 0 0 0 6873 0 21317 0 200004 0 0 0 LINDA HAWKINS DIR. QUALITY ASSURANCE & COMPLIANCE 160321 0 0 0 0 0 6413 0 17841 0 184575 0 0 0 NEIL O'CONNOR PRESIDENT & COO 162179 0 0 0 0 0 6333 0 14797 0 183309 0 0 0 ROBRICK SMITH DIRECTOR, INFORMATION TECHNOLOGY 156276 0 0 0 0 0 4688 0 21240 0 182204 0 0 0 CYNTHIA SHUMATE GENERAL COUNSEL & SEC. THRU 07/20 157812 0 0 0 0 0 6313 0 8564 0 172689 0 0 0 PART I, LINE 3 SHELLY CROCKER LLC REVIEWED/ESTABLISHED COMPENSATION OF CEO. SHELLY CROCKER LLC 35% CONTROLLED ENTITY 517900 RECEIVERSHIP FEES. SHELLY CROCKER LLC WAS APPOINTED RECEIVER OVER IDRI ON JANUARY 2, 2020, BY THE KING COUNTY SUPERIOR COURT, CASE NO. 20-2-00183-0 SEA. ALL PAYMENTS TO SHELLY CROCKER LLC HAVE BEEN SUBJECT TO COURT OVERSIGHT. 0 ABANDONMENT OF TENANT IMPROVEMENTS 2020-05-01 2025942 BOOK 0 0 0 0 FORM 990, SCHEDULE N, PART II: TO ADDRESS IDRI'S DETERIORATING CASH FLOW POSITION, IN LATE NOVEMBER AND DECEMBER 2019 TWO REDUCTIONS IN FORCE TOOK PLACE, REDUCING IDRI'S HEADCOUNT BY OVER 60%.HOWEVER, THESE ACTIONS PROVED INSUFFICIENT AND ON DECEMBER 20, 2019, AS FURTHER EFFORTS TO RESOLVE THE SITUATION PROVED UNSUCCESSFUL, IDRI'S BOARD OF DIRECTORS VOTED TO PLACE IDRI INTO VOLUNTARY WASHINGTON STATE RECEIVERSHIP AND THE BOARD WAS DISSOLVED. THE RECEIVERSHIP BECAME EFFECTIVE ON JANUARY 2, 2020.IDRI CURRENTLY HAS NO PLANS FOR DISSOLUTION OR LIQUIDATION. THE RECEIVER AND IDRI'S MANAGEMENT HAVE AND WILL CONTINUE TO RESTRUCTURE THE ORGANIZATION'S BUSINESS AND EXPECT TO SUCCESSFULLY EXIT RECEIVERSHIP SOMETIME IN THE FIRST QUARTER OF 2022. FORM 990, PART III, LINE 3 TUBERCULOSIS DRUG DISCOVERY CEASED AT THE END OF 2019. FORM 990, PART VI, SECTION A, LINE 8A BECAUSE THE ORGANIZATION ENTERED RECEIVERSHIP IN EARLY 2020, IT DID NOT HAVE A GOVERNING BODY FOR THE DURATION OF THE YEAR. FORM 990, PART VI, SECTION A, LINE 8B BECAUSE THE ORGANIZATION ENTERED RECEIVERSHIP IN EARLY 2020, IT DID NOT HAVE COMMITTEES FOR THE DURATION OF THE YEAR. FORM 990, PART VI, SECTION B, LINE 11B A DRAFT OF THE FORM 990 WAS PRESENTED TO THE RECEIVER FOR REVIEW AND COMMENT. FORM 990, PART VI, SECTION B, LINE 12C MEMBERS OF SENIOR MANAGEMENT ARE GIVEN A COPY OF THE CONFLICT OF INTEREST POLICY. THEY ARE REQUIRED TO FILL IT OUT AND RETURN IT IN THE FIRST QUARTER. THE CHIEF OPERATING OFFICER AND GENERAL COUNSEL REVIEW THE QUESTIONNAIRES AND SUMMARIZES THE RESULTS. THE RESULTS ARE COMMUNICATED TO THE RECEIVER. TO THE EXTENT THAT THERE ARE ANY CONFLICTS, THE MEMBER IS RECUSED FROM ANY DECISION MAKING THAT WOULD INCLUDE THE CONFLICT. WHEN THE OCCASION ARISES, THOSE MEMBERS ALSO REMIND THE MANAGEMENT TEAM THAT THERE IS A POTENTIAL CONFLICT WHEN SPECIFIC DISCUSSION TOPICS ARISE. AS PART OF BECOMING A COURT-APPOINTED RECEIVER IN A RECEIVERSHIP, THE RECEIVER MUST CONFIRM THAT THE RECEIVER HAS NO CONFLICTS OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 THE RECEIVER REVIEWED AND APPROVED THE COMPENSATION AND ANY COMPENSATION CHANGES OF ALL EMPLOYEES. FORM 990, PART VI, SECTION C, LINE 19 REQUESTS FOR INFORMATION SUCH AS AUDITED FINANCIAL STATEMENTS, GOVERNING DOCUMENTS, AND CONFLICT OF INTEREST POLICY ARE HANDLED THROUGH OUR FINANCE DEPARTMENT AND INFORMATION IS DISTRIBUTED AS REQUESTED UNLESS CONFIDENTIAL IN NATURE. FORM 990, PART VI, LINE 1: AS IDRI ENTERED RECEIVERSHIP IN JANUARY 2020, THE RECEIVER REPLACED A BOARD OF DIRECTORS AS THE ORGANIZATION'S GOVERNING BODY. AN EXECUTIVE LEADERSHIP TEAM WAS ESTABLISHED TO REVIEW AND DISCUSS ORGANIZATIONAL DECISIONS, BUT THE FINAL AUTHORITY RESTED WITH THE RECEIVER. FORM 990, PART XI, LINE 9: DEFERRED RENT LIABILITY ADJUSTMENT 3,421,222. FORM 990, PART XII, LINE 3B: AT THE TIME OF 2020 FORM 990 FILING, THE REQUIRED AUDIT UNDER THE SINGLE AUDIT ACT AND OMB CIRCULAR A-133 WAS STILL IN PROCESS. FORM 990, PART XII, LINE 2B: THE ORGANIZATION IS UNDERGOING A FINANCIAL STATEMENT AUDIT BUT IT WILL NOT BE COMPLETE AT THE TIME OF FILING THE FORM 990.